Compare Nokia Corp (NOK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs TG Therapeutics Inc — how do they compare? Nokia Corp trades at $10.36 (market cap $56.99B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Nokia Corp is far larger — about 7× TG Therapeutics Inc's market cap, and Nokia Corp pays a 1.61% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and TG Therapeutics Inc for 16 Days on average.
| NOK | TGTX | |
|---|---|---|
Market Cap | $56.99B | $8.16B |
Volume | 69,968,204 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $16.83 | $59.06 |
52-Week Low | $5.18 | $26.94 |
Typical Hold Time | 66 Days | 16 Days |
Enterprise Value | $55.01B | $8.37B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.14, down 4.52% today, amid bearish technical signals but strong analyst support. The stock shows mixed fundamentals with a high P/E ratio of 75.09 but improving revenue trends, with 2026 revenue projected at $20.4B. Recent partnerships with Microsoft and ICEYE for AI and satellite communications highlight growth initiatives. Cash flow volatility remains a concern with negative net cash flow in 2025 and 2026.
The outlook is cautiously optimistic with a consensus price target of $17.50 representing 73% upside potential. Key opportunities include AI infrastructure demand and expanding partnerships, while risks involve cash flow instability and competitive pressures in telecom equipment. Analyst sentiment is strongly bullish with 62% buy ratings, though technical indicators suggest near-term weakness.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
